Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus helveticus R0052
- Development stage
- Preclinical
- Lead developer
- Lallemand Health Solutions
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus helveticus R0052 is a well-characterized probiotic strain developed by Lallemand Health Solutions. It is primarily utilized for its ability to modulate the intestinal microbiota and strengthen the gut mucosal barrier. Preclinical studies, such as those involving DSS-induced colitis models, demonstrate its capacity to reduce systemic inflammation, restore metabolic homeostasis, and prevent the proliferation of pathogenic bacteria. Clinically, it is often investigated for its role in the gut-brain axis, particularly in reducing symptoms of psychological stress and anxiety, and is a component of several commercial probiotic formulations targeting gastrointestinal health.
- Other names
- Lactobacillus helveticus Rosell-52L. helveticus R0052Lactobacillus helveticus strain R0052
Beyond the preview
Go deeper on lactobacillus helveticus R0052.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus helveticus R0052.